Login / Signup

ACE I/D genotype associates with strength in sarcopenic men but not with response to ACE inhibitor therapy in older adults with sarcopenia: Results from the LACE trial.

Christos RossiosTufail BashirMarcus AchisonSimon AdamsonAsangaedem AkpanTerry AsprayAlison AvenellMargaret M BandLouise A BurtonVera CvoroPeter T DonnanGordon W DuncanJacob GeorgeAdam L GordonCelia L GregsonAdrian HapcaCheryl HumeThomas A JacksonSimon KerrAlixe H M KilgourTahir MasudAndrew McKenzieEmma McKenzieHarnish P PatelKristina PilvinyteHelen C RobertsAvan A SayerKaren T SmithRoy Louis SoizaClaire J StevesAllan D StruthersDivya TiwariJulie WhitneyMiles D WithamPaul R Kemp
Published in: PloS one (2023)
Our results suggest that although ACE genotype was not associated with response to ACE inhibitor therapy in the LACE trial population, sarcopenic men with the ACE DD genotype may be weaker than those with the ACE I/D or II genotype.
Keyphrases
  • angiotensin converting enzyme
  • angiotensin ii
  • middle aged
  • clinical trial
  • study protocol
  • phase iii
  • phase ii
  • randomized controlled trial
  • stem cells
  • physical activity
  • open label
  • mesenchymal stem cells
  • cell therapy